The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

February 6, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a cheaper biosimilar form of Johnson & Johnson’s arthritis drug Remicade (infliximab) that could eventually batter sales of the branded product.

You Might Also Like
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • FDA Panel Backs Amgen Biosimilar of Humira
  • Antibodies to Remicade Cross-React with Biosimilar Remsima

The panel, by a vote of 21-3, supported use of the biosimilar from Celltrion Inc. and Pfizer Inc., called Remsima. The FDA usually, but not always, follows the advice of its advisory panels.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The independent panel determined that clinical trials of Remsima showed no clinically significant differences with Remicade in treatment of rheumatoid arthritis and ankylosing spondylitis.

Moreover, the panel agreed Remsima is likely as safe and effective for other conditions Remicade treats, including psoriasis and inflammatory bowel conditions, such as Crohn’s disease and ulcerative colitis, even though Remsima was not tested against those conditions.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Before the vote, Jay Siegel, J&J’s chief biotechnology officer, urged the panel to await results of an ongoing Celltrion study comparing Remsima and Remicade against inflammatory bowel disease before assuming that the medicines are similar in those conditions.

“Only direct clinical comparisons of (Remsima) and Remicade in active inflammatory bowel disease can provide the requisite assurance,” he said.

But the FDA has previously determined it may be appropriate to license biosimilars for additional conditions for which a branded product is approved, even if the biosimilar has not been tested for them.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Steven Solga, head of gastroenterology at St. Luke’s University Hospital in Bethlehem, Pennsylvania, told the panel it makes no sense to require biosimilars to be tested for every condition because such trials would be too small to deliver reliable results.

Some analysts expect Remsima to be introduced in the U.S. by 2018 and wrest sales from Remicade as well as from AbbVie’s Humira (adalimumab) and Amgen’s Enbrel (etanercept) , which also block the inflammation-causing protein tumor necrosis factor.

Celltrion and Pfizer have not disclosed what they might charge for Remsima, but a substantial discount from Remicade is expected.

Shares of J&J, AbbVie and Amgen fell sharply on Friday after FDA scientists issued a briefing paper backing Remsima. Shares of the drugmakers were little changed after-hours on Tuesday.

Remsima would become the second approved biosimilar in the United States, following Novartis AG’s September introduction of Zarzio. It is a version of Amgen’s Neupogen (filgrastim), which boosts white blood cells in patients who have undergone chemotherapy. Novartis priced Zarzio at a 15% discount to Neupogen.

Filed Under: Biologics & Biosimilars, Drug Updates, Spondyloarthritis Tagged With: Ankylosing Spondylitis, Celltrion Inc., FDA, Food and Drug Administration, infliximab, monoclonal antibody, Remsima, Rheumatoid Arthritis (RA)

You Might Also Like:
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • FDA Panel Backs Amgen Biosimilar of Humira
  • Antibodies to Remicade Cross-React with Biosimilar Remsima
  • FDA Panel Supports Novartis Biosimilar of Etanercept

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)